Valmet's Half Year Financial Review for January-June 2026
On July 24, 2026, Valmet, a global technology leader in serving process industries, presented its financial results for the first half of 2026. The company's performance during the second quarter showed promising signs of growth, despite facing a challenging market environment. In this article, we'll delve into the highlights of Valmet's financials, discussing key metrics and future outlooks from the company's leadership.
Overview of Financial Performance
For the period of April to June 2026, Valmet reported a
6% increase in net sales, reaching
EUR 1,315 million compared to
EUR 1,241 million in Q2 2025. This growth is particularly significant as it indicates a recovery in demand in some segments, especially in Biomaterial Solutions and Services, which saw an uptick in sequential performance.
However, the total
orders received for the quarter fell by
10%, totaling
EUR 1,373 million, down from
EUR 1,520 million in the same quarter the previous year. This decrease is mainly attributed to a slump in capital project order intake within the Biomaterial Solutions segment, signaling a cautious approach from customers in today's volatile market.
Key Financial Metrics
For the half-year period from January to June 2026, Valmet's net sales rose by
6%, reaching
EUR 2,560 million, up from
EUR 2,426 million year-on-year. Additionally, the
Comparable EBITA for the first half of the year stood still at
EUR 266 million, marking a slight increase, but maintaining the same figure as the previous year.
Earnings per share (EPS) experienced a notable surge, increasing to
EUR 0.59 from
EUR 0.48 the prior year, reflecting a positive trajectory despite the overall market hesitation.
Key Figures Summary
- - Orders Received (Q2 2026): EUR 1,373 million (10% decrease)
- - Net Sales (Q2 2026): EUR 1,315 million (6% increase)
- - Comparable EBITA (Q2 2026): EUR 152 million (6% increase)
- - EPS (Q2 2026): EUR 0.40 (100% increase)
- - Cash Flow from Operations: EUR 100 million, down from EUR 297 million
Market Analysis and Future Outlook
Despite the positive growth in net sales and EBITA, market uncertainties continue to cloud Valmet’s future prospects. The company’s guidance for 2026 remains unchanged, with expectations that net sales will generally align with last year’s levels, reflecting
EUR 5,197 million. Furthermore, the Comparable EBITA is anticipated to remain stable or show slight growth compared to the previous year's results of
EUR 620 million.
The short-term outlook reveals that Valmet projecting low year-over-year growth for its Process Performance Solutions sector, while the Biomaterial Solutions segment is expected to maintain a steady pace following a challenging start to the year.
Leadership Insights
Thomas Hinnerskov, Valmet’s President and CEO, emphasized the measures implemented in the past year that have contributed to the company’s growth. In a recent statement, he remarked, “In the second quarter of 2026, the decisive actions we took last year to strengthen Valmet's competitiveness continued to deliver—net sales grew organically, and comparable EBITA increased.”
The CEO also noted that the acquisition of Severn, closing just after the quarter ended, will significantly enhance Valmet’s offerings and strengthen its capabilities in the Process Performance Solutions business, positioning it for future growth.
Conclusion
Valmet’s half-year financial review signals resilience, with key growth areas evident in net sales and earnings per share. As the company navigates through a complex market landscape marked by geopolitical uncertainties, its strategic initiatives and recent acquisitions could forge a pathway toward a more robust operational framework. Stakeholders and market watchers will closely monitor how Valmet adapts its strategies and seizes opportunities through the remainder of 2026.
Valmet continues its commitment to innovation and customer service, leveraging its long legacy and expertise to foster lasting relationships in the industries it serves.